Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri (Limosilactobacillus reuteri) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.
Ivashkin V, Maev I, Poluektova E, Sinitsa A
Published in Clinical and Translational Gastroenterology
Methodology
Randomized, double-blind, placebo-controlled multicenter trial of Pylopass 200 mg twice daily alongside 14-day triple therapy
Key Findings
Eradication was 96.7% with the postbiotic vs 86.0% with placebo (P = 0.039), with fewer digestive adverse effects.
Conclusions
Inactivated L. reuteri DSM 17648 improved eradication rates and tolerability as adjuvant therapy.
Limitations
Single-region multicenter trial; quality-of-life and symptom improvements did not differ between groups.
Supplements Studied
Eradication efficiency was 96.7% for the postbiotic group vs 86.0% for the placebo group (P = 0.039).
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.